GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » EV-to-Revenue

VRAX (Virax Biolabs Group) EV-to-Revenue : -45.09 (As of Jun. 24, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Virax Biolabs Group's enterprise value is $-3.83 Mil. Virax Biolabs Group's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $0.09 Mil. Therefore, Virax Biolabs Group's EV-to-Revenue for today is -45.09.

The historical rank and industry rank for Virax Biolabs Group's EV-to-Revenue or its related term are showing as below:

VRAX' s EV-to-Revenue Range Over the Past 10 Years
Min: -962.98   Med: -8.12   Max: 1001.52
Current: -45.09

During the past 5 years, the highest EV-to-Revenue of Virax Biolabs Group was 1001.52. The lowest was -962.98. And the median was -8.12.

VRAX's EV-to-Revenue is ranked better than
98.29% of 995 companies
in the Biotechnology industry
Industry Median: 7.6 vs VRAX: -45.09

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-24), Virax Biolabs Group's stock price is $0.7906. Virax Biolabs Group's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.04. Therefore, Virax Biolabs Group's PS Ratio for today is 20.81.


Virax Biolabs Group EV-to-Revenue Historical Data

The historical data trend for Virax Biolabs Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group EV-to-Revenue Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-Revenue
- - - 153.83 -11.20

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only - 153.83 - -11.20 -

Competitive Comparison of Virax Biolabs Group's EV-to-Revenue

For the Biotechnology subindustry, Virax Biolabs Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virax Biolabs Group's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's EV-to-Revenue falls into.


;
;

Virax Biolabs Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Virax Biolabs Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-3.833/0.085
=-45.09

Virax Biolabs Group's current Enterprise Value is $-3.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Virax Biolabs Group  (NAS:VRAX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Virax Biolabs Group's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.7906/0.038
=20.81

Virax Biolabs Group's share price for today is $0.7906.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Sep. 2024 was $0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Virax Biolabs Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Virax Biolabs Group Business Description

Traded in Other Exchanges
N/A
Address
Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.